Miniatura

Fitxers

s13045-024-01608-8.pdf (2.25 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-10-29

Llicència de publicació

cc-by-nc-nd (c) Iacoboni, Gloria et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/217361

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13045-024-01608-8

Resum

Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient population is lacking. A training cohort of 216 patients with progressive disease (PD) after CAR-T from 12 Spanish centers was used to develop the Post-CAR Prognostic Index (PC-PI); primary endpoint was overall survival (OS) from CAR-T progression. Validation was performed in an external cohort from three different European centers (n = 204). The prognostic score incorporated five variables, assessed at time of PD to CAR-T: ECOG (> 0), hemoglobin (< 10 g/dL), LDH (>= 2xULN), number of extranodal sites (> 1) and time from CAR-T to PD (< 4 months). Patients were classified in four risk groups with distinct OS (p-value < 0.05 in all comparisons). In the validation cohort, median OS in the low (31%), intermediate-low (26%), intermediate-high (17%) and high risk (26%) were 15.7, 7.1, 1.8 and 1.0 months, respectively (p < 0.05 in all comparisons). Results were consistent following adjustment for subsequent treatment. In the external cohort, the PC-PI showed a C-statistic of 0.79 (95%CI 0.76-0.82), outperforming IPI and R-IPI. In conclusion, the PC-PI score is a novel tool for OS prediction and could facilitate risk-adapted management of LBCL patients relapsing after CAR T-cells. Additionally, these results will help stratification and interpretation of trials and real-world data incorporating CART-exposed patients.

Matèries

Limfomes, Cèl·lules B

Matèries (anglès)

Lymphomas, B cells

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

IACOBONI, Gloria, NAVARRO, Víctor, SESQUES, Pierre, REJESKI, Kai, BASTOS OREIRO, Mariana, SERPENTI, Fabio, MARTIN LOPEZ, Ana africa, IRAOLA TRUCHUELO, Josu, DELGADO, Javier, PEREZ, Ariadna, GUERREIRO, Manuel, CABALLERO, Ana carolina, MARTINEZ CIBRIAN, Nuria, LUZARDO HENRIQUEZ, Hugo, SANCHEZ PINA, Jose maria, SANCHO, Juan manuel, GHESQUIERES, Hervé, MUSSETTI, Alberto, LOPEZ CORRAL, Lucia, HERNANI, Rafael, REGUERA, Juan luís, SUREDA, Anna, BOSCH, Francesc, MARTIN GARCIA-SANCHO, Alejandro, KWON, Mi, SUBKLEWE, Marion, KUHNL, Andrea, BACHY, Emmanuel, BARBA, Pere, VILLACAMPA, Guillermo, ABRISQUETA, Pau. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment. _Journal of Hematology & Oncology_. 2024. Vol. 17. [consulta: 27 de gener de 2026]. ISSN: 1756-8722. [Disponible a: https://hdl.handle.net/2445/217361]

Exportar metadades

JSON - METS

Compartir registre